

How should a clinician interpret results of randomized controlled trials?

Interpretation of randomized controlled trials

Virginijus Šapoka¹,

Vytautas Kasiulevičius¹,

Janina Didžiapetrienė^{1,2}

¹ Faculty of Medicine,
Vilnius University, Vilnius,
Lithuania

² Institute of Oncology,
Vilnius University, Vilnius,
Lithuania

Randomized controlled trials (RCTs) and systematic reviews are the most reliable methods of determining the effects of treatment. The randomization procedure gives a randomized controlled trial its strength. Random allocation means that all participants have the same chance of being assigned to each of the study groups. The choice of which end point(s) to select is critical to any study design. Intention-to-treat is the preferred approach to the analysis of clinical trials. Sample size calculations and data analyses have an important impact on the planning, interpretation, and conclusions of randomized trials. In this article, we discuss the problematic areas that can affect the outcome of a trial, such as blinding, sample size calculation, randomization; concealment allocation; intention of treating the analysis; selection of end points; selection of traditional versus equivalence testing, early stopped trials, selective publications.

Key words: randomized controlled trials, sample size, outcomes, type of analyses

INTRODUCTION

Randomized controlled trials (RCTs) and systematic reviews are the most reliable methods of determining the effects of treatment. Ideally, trials are designed and conducted both to minimize the bias (i. e. have a high internal validity) and to be relevant to a wide but defined population (i. e. have a high external validity, also termed generalizability). There are problematic areas that can affect the outcome of a trial: blinding; sample size calculation, randomization; concealment allocation; intention to treat the analysis (the analytic method used); selection of end points; selection of traditional versus equivalence testing, early stopped trials, selection of publications. In our review, we address the questions such as what it is that leads the RCT to the highest level of evidence and what the features of the RCT that render it so useful are. In the article, we discuss a number of principles that answer these questions.

RESULTS AND DISCUSSION

Blinding in a clinical trial. The term “blinding” or “masking” refers to withholding information about the assigned interventions from people involved in the trial who may potentially be influenced by this knowledge. Blinding is an important safeguard against bias, particularly when assessing subjective outcomes. Blinding in a clinical trial can be defined as withholding information about treatment allocation from those who could potentially be influenced by this information. Unblinded studies exhibit an increased effect of treatment compared with blinded studies. In the section of methods, the authors should describe in some detail who was blinded, how they were blinded, and the success of blinding. Certainly participants and investigators can be blinded. Less commonly recognized is that data collectors and analysts should be blinded. Participants should be blinded because they may use other effective interventions, may report symptoms differently, or may drop out if they perceive they have received a placebo therapy. Investigators should be blinded because they may prescribe effective co-interventions, influence the follow-up, or patient reporting. Data collectors and

analysts should be blinded because they may exhibit different encouragement during performance testing, exhibit variable recordings of outcomes, or different timing and frequency of outcome measurements. There is no universal agreement on how to assess blinding or even whether it should be assessed. Study authors often ask investigators and participants to guess their treatment allocation and report the results. Some would suggest looking for bias-generating consequences instead of contamination and co-interventions. The measurement bias is defined as an inaccurate measurement due to either the accuracy of the measurement instrument or a bias based upon the expectations of participants and investigators. Blinding will help to limit measurement bias (1, 2).

Randomization. The randomization procedure gives a randomized controlled trial its strength. Random allocation means that all participants have the same chance of being assigned to each of the study groups. The allocation, therefore, is not determined by the investigators, the clinicians, or the study participants. The purpose of random allocation of participants is to assure that the characteristics of the participants are as likely to be similar as possible across groups at the start of the comparison (also called the baseline). If randomization is done properly, it reduces the risk of a serious imbalance in the known and unknown factors that could influence the clinical course of the participants. No other study design allows investigators to balance these factors (1, 2).

Concealment allocation. After the randomization sequence is generated, the list may be given to the investigator responsible for enrolling participants in the study. This is referred to as unconcealed participant allocation. The investigator may steer participants to certain treatment arms based upon prognostic factors either consciously or unconsciously. Concealment allocation can be defined as the process by which the physician is blinded to the randomized sequence which was generated. The person who enrolls participants in the trial should not be the same person who generates the allocation sequence. In RCTs where concealment allocation has not been utilized, there is an overestimation of treatment effect compared to trials which conceal the allocation sequence. The treatment effect may increase by 20 to 30%. The average bias associated with the lack of adequate concealment allocation was less for outcomes that were evaluated objectively (death, ulcer closure) rather than subjectively (pain, patient-reported outcomes) (1, 2). The allocation concealment should not be confused with blinding. Allocation concealment seeks to prevent selection bias, protects the assignment sequence until allocation and can always be successfully implemented. In contrast, blinding seeks to prevent performance and ascertainment bias, protects the sequence after allocation, and cannot always be implemented. Without adequate allocation concealment, however, even random, unpredictable assignment sequences can be subverted.

Discrepancies in sample size calculations. Sample size calculations and data analysis have an important impact on the planning, interpretation, and conclusions of randomized

trials. Statistical analysis often involves several subjective decisions about which data to include and which tests to use, producing potentially different results and conclusions depending on the decisions taken. The methods of analysis that are chosen or altered after preliminary examination of the data can introduce bias if a subset of favourable results is then reported in a publication. The study protocol plays a key role in reducing such bias by documenting a pre-specified blueprint for conducting and analyzing a trial. Explicit descriptions of methods before a trial starts help identify and deter unacknowledged, potentially biased changes made after reviewing the study results. To evaluate the completeness and consistency of reporting, we reviewed a comprehensive cohort of randomised trials and compared the sample size calculations and data analysis methods described in the protocols with those reported in the publications (3, 4).

Superiority versus equivalence trials. Most trials test whether a new treatment is superior to a control (placebo) group or conventional standard of care. A superiority trial aims to demonstrate the superiority of a new therapy compared to an established therapy or placebo. In contrast, some trials are designed to show that a new treatment is not inferior to standard therapy by a predefined acceptable amount. Several problems challenge the design, conduct, analysis, reporting, and interpretation of noninferiority trials, and recent meta-analyses confirm that the majority of published trials have substantial methodologic flaws (5). As a result, potentially suboptimal treatments might be introduced into routine clinical practice. Other issues that are crucial to ensuring the validity of noninferiority inference, such as ethical considerations, adequate power, the quality of trial conduct, the choice of analytic strategy (intention-to-treat versus per-protocol), and an alternative Bayesian approach to analysis, are beyond the scope of this paper and have been detailed previously (6, 7). In conclusion, if noninferiority trials are to be applied to regulatory and clinical decisions about the marketing and use of new treatments, their assumptions must be made explicit, the criteria on which they are based must be sufficiently justified, and their influence on the resultant conclusions must be assessed rigorously and expressed unambiguously in published reports (8, 9).

Intention-to-treat or on treatment analyses. There are three general analytic approaches in clinical trials: analysis as randomized (referred to as intention-to-treat analysis, or ITT), compliers-only analysis (in which only those patients randomized to a treatment who completed the trial and complied with treatment are analyzed), and as-treated analysis (in which only those who received a given treatment are counted, whether or not the patient was initially assigned to that treatment). Intention-to-treat analysis is a method of analysis for randomized trials in which all patients randomly assigned to one of the treatments are analyzed together, regardless of whether or not they completed or received that treatment. Intention-to-treat analysis prevents a bias caused by the loss of participants, which may disrupt the baseline equivalence

established by random assignment and which may reflect non-adherence to the protocol. Intention-to-treat (ITT) analysis is commonly accepted as more conservative than the per-protocol (PP) restricted to the analysis of data on subjects who completed the study. Commonly, the within-groups differences being smaller in ITT than in PP, their statistical comparison leads to a smaller risk of type I error (i. e. inappropriately concluding a difference while there is not any). It also allows for keeping the randomization scheme (i. e. the balanced distribution of confounding factors) and thus not lead to a differential distribution of confounding factors among the groups if more subjects are withdrawn from the study in a given group (10).

Surrogate outcomes. The choice of which end point(s) to select is critical to any study design. Two additional areas require particular attention: the use of surrogate measures and the use of composite end points. The most persuasive trials are ones that use clinical events or well-accepted surrogate variables as their outcomes. Trials with surrogate outcomes typically are smaller in size and therefore much less costly. Surrogate outcomes are often a measure of the underlying disease process (e. g., C-reactive protein), a measurement of preclinical disease (e. g., coronary artery calcifications), or an etiologically relevant, well-accepted risk factor (e. g., systolic BP, LDL cholesterol). The list of candidate surrogate outcomes is huge, but only a few are so well accepted that the trials that use these variables actually influence the policy. However, policy-making committees and bodies have not always been influenced by the results of trials with surrogate outcomes, because the clinical relevance of most surrogate outcomes is uncertain (11–14).

Subgroup or post-hoc analyses. Subgroup analyses are an important part of the analysis of a comparative clinical trial. However, they are commonly overinterpreted and can misguide further research or, worse, to result in suboptimal patient care. A randomized clinical trial is designed to determine whether a new treatment is more effective than an established one and assessed with a test, based on all randomized patients, of the null hypothesis that the treatments have equal efficacy as measured in terms of the primary end point. Then, subgroup analyses are conducted to assess whether different types of patients respond differently to the new treatment. This sounds simple enough, but there are several important sources of confusion and uncertainty regarding such subgroup analysis. Clinicians should be wary of trials that report many subgroup analyses, unless the investigators provide valid reasons. Also, beware of trials that provide a small number of subgroup analyses. They might have done many and just cherry-picked the interesting and significant ones. Consequently, faulty reporting could mean that trials with few subgroup analyses are even worse than trials with many. Investigators find more credence if they state that they reported all the analyses done. Furthermore, researchers should label non-prespecified subgroup analyses as hypothesis-generating rather than confirming. Such find-

ings should not appear in the conclusions. Clinicians should expect interaction tests for subgroup effects. Discount analyses are built on tests within subgroups. Even with a significant interaction test, readers should base the interpretation of the findings on biological plausibility, on prespecification of analyses, and on the statistical strength of the information. Generally, adjustments for multiplicity are unnecessary when investigators use interaction tests. However, in view of the frequently frivolous data-dredging pursuits involved, the argument for statistical adjustments is stronger than that for multiple endpoints. Moreover, if investigators do not use interaction tests and report tests on every individual subgroup, multiplicity adjustments are appropriate. Most subgroup findings tend to exaggerate reality. Be especially suspicious of investigators highlighting a subgroup treatment effect in a trial with no overall treatment effect (15–19).

RCTs stopped early for benefit. When randomized clinical trials (RCTs) identify larger than expected treatment effects, investigators may conclude, before completing the trial as planned, that one treatment is superior to the other. Such trials often receive considerable attention. Clinicians face challenges when interpreting the results of truncated RCTs. Taking the point estimate of the treatment effect at face value will be misleading if the decision to stop the trial resulted from catching the apparent benefit of treatment at a “random high”. When this occurs, data from future trials will yield a more conservative estimate of treatment effect, the so-called regression to the truth effect. Thus, clinicians must attend not only to the usual methodological safeguards against bias, but also to the characteristics that affect the decision to stop a trial early. Such characteristics include the plausibility of the treatment effect, the planned sample size, the number of interim analyses after which the investigators stopped the RCT, and the statistical methods used to monitor the trial and to adjust estimates, *p* values, and confidence intervals for interim analyses. While RCTs stopped early for reasons other than benefit might share some characteristics with RCTs stopped early for benefit, their implications are very different. Trials stopped early because of harm or futility tend to result in a decreased use or prompt discontinuation of useless or potentially harmful interventions. In contrast, trials stopped early for benefit may result in a rapid identification, approval and dissemination of promising new treatments (20–23).

Selective publications. Another common problem is that the pharmaceutical industry can choose which data to publish and which to leave unavailable. Much has been written on eye-catching stories, such as the difficulties in getting clear information about the number of suicide attempts in industry trials of SSRI antidepressants, or the number of heart attacks in patients on rofecoxib. Equally concerning is the routine grind of publication bias, where disappointing negative results on the benefits of treatments quietly disappear (24). Medical decisions are based on the understanding of publicly reported clinical trials. If the evidence base is biased, then decisions based on this evidence may not be the optimal

decisions. For example, selective publications of clinical trials and the outcomes within those trials, can lead to unrealistic estimates of drug effectiveness and alter the apparent risk-benefit ratio. Attempts to study selective publications are complicated by the unavailability of data from unpublished trials. Researchers have found evidence for selective publication by comparing the results of published trials with information from surveys of authors, registries, institutional review boards, and funding agencies, and even with published methods. Numerous tests are available to detect a selective-reporting bias, but none are known to be capable of detecting or ruling out bias reliably (25–31).

CONCLUSIONS

Although RCTs remain a gold standard proof of efficacy, there are many aspects of trial design that must be appropriately incorporated to ensure the value of a study. An inappropriate use of any tool (including RCTs) compromises the ability to meaningfully interpret the resulting information. We have presented several aspects should be considered by a user of the information when establishing the credence to attach to the information from a RCT.

Received 9 April 2010

Accepted 27 May 2010

References

1. Appel LJ. A primer on the design, conduct, and interpretation of clinical trials. *Clin J Am Soc Nephrol*. 2006; 1(6): 1360–7.
2. Grimes DA, Schultz KF. An overview of clinical research: the lay of the land. *Lancet*. 2002; 339(9300): 57–61.
3. Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P. Reporting of sample size calculation in randomised controlled trials: review. *BMJ*. 2009; 338: b1732.
4. Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. *BMJ*. 2008; 337: a2299.
5. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. *JAMA*. 2006; 295(10): 1147–51.
6. Altman DG. *Practical Statistics for Medical Research*. London: Chapman & Hall; 1991. 611 p.
7. Wiens BL. Something for nothing in noninferiority / superiority testing: a caution. *Drug Inf J*. 2001; 35(1): 241–5.
8. D'Agostino RB Sr, Massaro J, Sullivan L. Non-inferiority trials: design concepts and issues – the encounters of academic consultants in statistics. *Stat Med*. 2003; 22(2): 169–86.
9. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. *Ann Intern Med*. 2006; 145(1): 62–9.
10. Wiens BL, Zhao W. The role of intention to treat in analysis of noninferiority studies. *Clin Trials*. 2007; 4(3): 286–91.
11. Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. *JAMA*. 1999; 282(8): 786–90.
12. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? *Ann Intern Med*. 1996; 125(7): 605–13.
13. Krumholz HM. Outcomes research: generating evidence for best practice and policies. *Circulation*. 2008; 118(3): 309–18.
14. Krumholz HM. Outcomes research: myths and realities. *Circ Cardiovasc Qual Outcomes*. 2009; 2(1): 1–3.
15. Lagakos SW. The challenge of subgroup analyses – reporting without distorting. *N Engl J Med*. 2006; 354(16): 1667–9.
16. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other mis(uses) of baseline data in clinical trials. *Lancet*. 2000; 355(9209): 1064–9.
17. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting. *Stat Med*. 2002; 21(19): 2917–30.
18. Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. *Lancet*. 2005; 365(9471): 1657–61.
19. Ke-Hai Yuan KH, Maxwell S. On the post hoc power in testing mean differences. *J Educ Behav Stat*. 2005; 30(2): 141–67.
20. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Egger CH, Briel M, Lacchetti C, Leung TW, Darling E et al. Randomized trials stopped early for benefit: a systematic review. *JAMA*. 2005; 294(17): 2203–9.
21. Pocock S, White I. Trials stopped early: too good to be true? *Lancet*. 1999; 353(9157): 943–4.
22. Guyatt G, Rennie D. *Users' guides to the medical literature*. *JAMA*. 1993; 270(17): 2096–7.
23. Kaul S, Diamond GA. Trial and error. How to avoid commonly encountered limitations of published clinical trials. *J Am Coll Cardiol*. 2010; 55(5): 415–27.
24. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med*. 2008; 358(3): 252–60.
25. Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, Chalmers TC. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. *Arch Intern Med*. 1994; 154(2): 157–63.
26. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. *BMJ*. 2003; 326(7400): 1167–70.
27. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. *J Nerv Ment Dis*. 2002; 190(9): 583–92.
28. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic

- review of randomised controlled trials. *BMJ*. 2005; 330(7488): 396.
29. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population-based nested case-control analysis. *BMJ*. 2005; 330(7504): 1366.
 30. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med*. 2008; 358(3): 252–60.
 31. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA*. 1995; 273(5): 408–12.

Virginijus Šapoka, Vytautas Kasiulevičius,
Janina Didžiapetrienė

KAIP KLINICISTAI TURĖTŲ VERTINTI ATSITIKTINIŲ IMČIŲ KONTROLIUOJAMUS TYRIMUS?

S a n t r a u k a

Atsitiktinių imčių kontroliuojami tyrimai ir sisteminės apžvalgos yra patikimiausi metodai gydymo efektui nustatyti. Randomizacijos procedūra yra atsitiktinių imčių kontroliuojamų tyrimų stiprioji pusė. Atsitiktinis paskirstymas reiškia, kad bet kuris tyrimo dalyvis turi vienodą progą patekti į kiekvieną grupę. Vertinamų rezultatų pasirinkimas yra kritiškai svarbus bet kokiam tyrimui. Rekomenduojamas klinikinių tyrimų būdas – ketinamų gydyti pacientų analizė. Šiame straipsnyje mes aptariame problemines sritis, kurios gali turėti įtakos mokslinio tyrimo rezultatams: maskavimo metodiką, imties dydžio nustatymą, atsitiktinę atranką, paslėptą paskirstymą, ketinamų gydyti pacientų analizę, rezultatų vertinimą, ekvivalentiškumo tyrimus, anksčiau numatyto laiko tyrimų stabdymą.

Raktažodžiai: atsitiktinės atrankos tyrimas, imties dydis, rezultatai, analizės tipas